Who can benefit more from its twelve-week treatment: A prospective cohort study of blonanserin for patients with schizophrenia

Table 3 Major adverse drug reactions involving systematic and clinical manifestations

ADRs	Mild patients, n (%)	Mild cases	Moderate patients, n (%)	Moderate cases	Severe patients, n (%)	Severe cases
Total ADRs	443 (13.4)	656	164 (5.0)	219	15 (0.5)	16
Neurological disorders	352 (10.6)	420	127 (3.8)	159	7 (0.2)	8
Akathisia	170 (5.1)	174	66 (2.0)	68	4 (0.1)	4
Tremor	97 (2.9)	100	27 (0.8)	27	0 (0)	0
Dystonia	54 (1.6)	54	23 (0.7)	24	2 (0.1)	2
Parkinsonism	43 (1.3)	44	22 (0.7)	22	1 (0.0)	1
Investigations	74 (2.2)	85	23 (0.7)	25	3 (0.1)	3
Elevated transaminase level	6 (0.2)	6	0 (0)	0	0 (0)	0
Weight gain	34 (1.0)	34	5 (0.2)	5	0 (0)	0
Increased blood prolactin	20 (0.6)	20	12 (0.4)	12	1 (0.0)	1
Increased blood glucose	2 (0.1)	2	1 (0.0)	1	1 (0.0)	1
Decreased white blood cell count	2 (0.1)	2	1 (0.0)	1	0 (0)	0
Prolonged electrocardiogram QT	2 (0.1)	2	0 (0)	0	1 (0.0)	1
Gastrointestinal disorders	48 (1.5)	50	11 (0.3)	11	0 (0)	0
Eye disorders	8 (0.2)	10	1 (0.0)	1	0 (0)	0
Psychiatric disorders	16 (0.5)	18	4 (0.1)	5	0 (0)	0
Kidney and urinary disorders	2 (0.1)	2	4 (0.1)	4	1 (0.0)	1

ADR: Adverse drug reactions.